122 related articles for article (PubMed ID: 32196836)
1. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study.
Saad A; Goldstein J; Margalit O; Shacham-Shmueli E; Lawrence YR; Yang YX; Reiss KA; Golan T; Mamtani R; Halpern N; Aderka D; Mouallem M; Goldstein A; Giantonio B; Boursi B
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):599-604. PubMed ID: 32196836
[TBL] [Abstract][Full Text] [Related]
2. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.
Huang YL; Lai CC; Wang YH; Wang CY; Wang JY; Wang HC; Yu CJ; Chen L
Int J Chron Obstruct Pulmon Dis; 2017; 12():2987-2996. PubMed ID: 29066880
[TBL] [Abstract][Full Text] [Related]
3. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study.
Kirkegård J; Cronin-Fenton D; Lund A; Mortensen FV
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5726. PubMed ID: 37946571
[TBL] [Abstract][Full Text] [Related]
4. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
[TBL] [Abstract][Full Text] [Related]
5. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
6. Digoxin use is associated with pancreatic cancer risk but does not affect survival.
Boursi B; Huber JS; Haynes K; Mamtani R; Yang YX
Cancer Causes Control; 2021 Jan; 32(1):41-46. PubMed ID: 33064241
[TBL] [Abstract][Full Text] [Related]
7. An assessment of the association between carvedilol exposure and severe hypersensitivity reactions, angioedema, and anaphylactic reactions: a retrospective nested case-control analysis.
Koro CE; Sowell MD; Stender M
Clin Ther; 2012 Apr; 34(4):870-7. PubMed ID: 22444788
[TBL] [Abstract][Full Text] [Related]
8. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.
Mandilaras V; Bouganim N; Yin H; Asselah J; Azoulay L
Br J Cancer; 2017 Jan; 116(1):103-108. PubMed ID: 27846200
[TBL] [Abstract][Full Text] [Related]
9. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study.
Brauchli YB; Jick SS; Curtin F; Meier CR
Br J Dermatol; 2008 Jun; 158(6):1299-307. PubMed ID: 18410416
[TBL] [Abstract][Full Text] [Related]
10. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma.
Udumyan R; Montgomery S; Fang F; Almroth H; Valdimarsdottir U; Ekbom A; Smedby KE; Fall K
Cancer Res; 2017 Jul; 77(13):3700-3707. PubMed ID: 28473530
[TBL] [Abstract][Full Text] [Related]
11. Ion channel blockers and glioblastoma risk and outcome: a nested case-control and retrospective cohort studies.
Boursi B; Han HJ; Haynes K; Mamtani R; Yang YX
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1179-1185. PubMed ID: 27384764
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive drugs and the risk of incident rosacea.
Spoendlin J; Voegel JJ; Jick SS; Meier CR
Br J Dermatol; 2014 Jul; 171(1):130-6. PubMed ID: 24428524
[TBL] [Abstract][Full Text] [Related]
13. β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
Gronich N; Abernethy DR; Auriel E; Lavi I; Rennert G; Saliba W
Mov Disord; 2018 Sep; 33(9):1465-1471. PubMed ID: 30311974
[TBL] [Abstract][Full Text] [Related]
14. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis.
Yang A; Zylberberg HM; Rustgi SD; Amin SP; Bar-Mashiah A; Boffetta P; Lucas AL
Sci Rep; 2021 Jan; 11(1):1038. PubMed ID: 33441781
[TBL] [Abstract][Full Text] [Related]
15. Total Serum Cholesterol and Pancreatic Cancer: A Nested Case-Control Study.
Chen WC; Boursi B; Mamtani R; Yang YX
Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):363-369. PubMed ID: 30333217
[TBL] [Abstract][Full Text] [Related]
16. Statin use and the risk of pancreatic cancer: a population-based case-control study.
Chiu HF; Chang CC; Ho SC; Wu TN; Yang CY
Pancreas; 2011 Jul; 40(5):669-72. PubMed ID: 21654539
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors on pancreatic cancer risk and survival.
Kearns MD; Boursi B; Yang YX
Cancer Epidemiol; 2017 Feb; 46():80-84. PubMed ID: 28056391
[TBL] [Abstract][Full Text] [Related]
18. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Hicks BM; Murray LJ; Powe DG; Hughes CM; Cardwell CR
Ann Oncol; 2013 Dec; 24(12):3100-6. PubMed ID: 24050955
[TBL] [Abstract][Full Text] [Related]
19. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies.
Jacobs EJ; Newton CC; Silverman DT; Nogueira LM; Albanes D; Männistö S; Pollak M; Stolzenberg-Solomon RZ
Cancer Causes Control; 2014 Sep; 25(9):1083-91. PubMed ID: 24913781
[TBL] [Abstract][Full Text] [Related]
20. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.
Cardwell CR; Coleman HG; Murray LJ; Entschladen F; Powe DG
Int J Epidemiol; 2013 Dec; 42(6):1852-61. PubMed ID: 24536096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
